Welcome to our dedicated page for Si-Bone SEC filings (Ticker: SIBN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SI-BONE, Inc. filings document formal disclosures for a Nasdaq-listed medical device company developing surgical technologies for compromised bone and sacropelvic disorders. Recent Form 8-K reports furnish quarterly results, preliminary revenue and cash information, Regulation FD presentation materials, and material agreements such as facility lease arrangements.
The company’s proxy materials cover annual meeting matters, board composition, executive compensation, equity awards, and pay-versus-performance disclosure. Additional 8-K disclosures record governance and leadership changes, including board resignations, committee updates, officer transitions, and related compensatory arrangements.
SI-BONE, Inc. director Timothy E. Davis Jr. reported an option exercise and related share sales. On May 28, 2026, he exercised options for 12,064 shares of common stock at $4.32 per share, then sold 3,780 shares at a weighted average price of $14.4706. On May 29, 2026, he sold an additional 3,500 shares at a weighted average price of $14.1394. Following these transactions, he held 65,722 shares directly. A footnote states that this holding includes 8,675 shares issuable on settlement of restricted stock units.
SIBN filed a Form 144 reporting a proposed sale of 3,500 shares of Common Stock described as restricted stock. The filing also records a sale by Timothy E. Davis Jr. of 3,780 shares on 05/28/2026 for $54,698.87.
SI-BONE, Inc.’s Chief Executive Officer Laura Francis reported open-market sales of 14,957 shares of common stock on May 18, 2026, at weighted average prices around the mid-$14 range. According to the disclosure, these shares were sold solely to cover tax withholding obligations tied to vesting restricted stock units and were not discretionary trades.
Following the sales, Francis directly holds 540,476 shares of SI-BONE common stock. She also has indirect ownership of additional shares held by a family trust, providing substantial ongoing equity exposure despite the tax-related share sales.
SI-BONE, Inc. senior vice president and chief legal officer Michael A. Pisetsky reported selling 3,726 shares of common stock on May 18, 2026 in open-market transactions at weighted average prices around $14.63 per share.
According to the disclosure, these sales were required to cover tax withholding obligations tied to the vesting of restricted stock units and were executed as automatic “sell to cover” transactions, not discretionary trades. He also holds 1,395 shares acquired under the 2018 Employee Stock Purchase Plan on May 15, 2026, and 143,729 shares issuable upon settlement of restricted stock units.
SI-BONE, Inc. Chief Financial Officer Anshul Maheshwari reported two open-market sales of common stock that were executed solely to cover tax withholding from vested restricted stock units. The transactions totaled 4,666 shares, sold at weighted average prices of $14.6545 and $14.7132 per share.
A footnote explains these were mandatory "sell to cover" trades and not discretionary sales. Another footnote notes 1,395 shares acquired under the 2018 Employee Stock Purchase Plan and 183,921 shares issuable upon settlement of outstanding restricted stock units, indicating a substantial remaining equity position tied to future vesting.
SI-BONE, Inc. reported strong first quarter 2026 results and raised its full-year 2026 outlook. Worldwide revenue grew 11.2% to $52.6 million, with U.S. revenue up 10.0% to $49.3 million and international revenue up 33.9% to $3.3 million.
Gross margin remained high at 79.8%, while net loss narrowed to $4.3 million or $0.10 per share, a 33.8% improvement from the prior year period. Adjusted EBITDA turned meaningfully higher to $2.5 million from $0.5 million, and cash and equivalents were $144.7 million as of March 31, 2026.
Management increased 2026 worldwide revenue guidance to $230–$233 million, implying approximately 14–16% growth, and raised the full-year gross margin expectation to about 79%, while reaffirming expectations for positive adjusted EBITDA.
SI-BONE, Inc. ownership update: First Light Asset Management, LLC and Mathew P. Arens jointly filed an Amendment No. 1 to Schedule 13G reporting beneficial ownership positions. The Manager reports 7,971,486 shares (18.02%) and Mr. Arens reports 8,120,986 shares (18.36%).
The filing explains the Manager acts as investment adviser to separate accounts and private funds and that Mr. Arens controls the Manager and also holds direct shares (23,000 sole; 126,500 joint). Signatures are provided by the Manager's CCO and Mr. Arens.
SI-BONE, Inc. director Jeffrey W. Dunn reported a small, non-discretionary share sale tied to taxes. On May 4, 2026, a total of 337 shares of Common Stock were sold at a weighted average price of $13.1508 solely to cover tax withholding obligations from the vesting of restricted stock units under a “sell to cover” arrangement. Following this transaction, Dunn holds 9,157 shares directly, which include 8,675 shares issuable upon settlement of restricted stock units, and 80,591 shares indirectly through The Jeffrey W. Dunn Living Trust.
BlackRock, Inc. amended a Schedule 13G to report beneficial ownership of 3,057,039 shares of SI-BONE, Inc. common stock, representing 6.9% of the class. The filing shows sole voting power for 2,997,105 shares and sole dispositive power for 3,057,039 shares. The amendment is signed by Spencer Fleming, Managing Director on 04/24/2026.